Abstract
BackgroundInfliximab, the chimeric monoclonal IgG antibody to tumour necrosis factor-alpha, is indicated for medically refractory luminal and fistulising paediatric Crohn’s disease. Also, for ulcerative colitis care series in children and...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have